#USA #San Francisco #Cancer Immunotherapy #Parker Institute #ASCO 2026

Parker Institute for Cancer Immunotherapy at ASCO 2026

The Parker Institute for Cancer Immunotherapy (PICI) has made its mark at the highly anticipated ASCO 2026 Annual Meeting, showcasing the valuable contributions of its integrated network in advancing cancer research. From May 29 to June 2, PICI's researchers, investigators, and collaborators are set to participate in more than 50 oral sessions, posters, and publications, reflecting the urgent and transformative nature of their work in the realm of cancer immunotherapy.

Comprehensive Research Coverage

The extensive body of work presented at ASCO spans a diverse array of cancer types, including glioblastoma, melanoma, prostate, breast, lung, and urothelial cancers. This impressive collection includes groundbreaking data on CAR T-cell and TIL-based therapies, tailored neoantigen vaccine strategies, and innovative immune profiling techniques aimed at understanding patient responses to checkpoint inhibitors.

Notably, PICI unveiled findings from its RADIOHEAD pan-cancer cohort, presenting new multimodal immunoprofiling data that utilizes advanced models of the immune system to predict treatment responses and potential toxicities. This research builds on previously shared data at the AACR earlier this year, demonstrating PICI's commitment to leveraging data science for precision medicine in oncology.

At ASCO 2026, PICI also plans to honor the inaugural recipient of the Conquer Cancer PICI Endowed Young Investigator Award. This initiative aims to recognize promising early-career clinical oncology researchers as they navigate their transition from fellowship training to faculty positions.

Insights from Leading Cancer Experts

Dr. Karen Knudsen, CEO of PICI, emphasized, "Cancer continues to demand urgency, and the PICI Network is designed to meet that challenge through coordinated, collaborative science. Our participation at ASCO 2026 reflects the strength of this model, bringing together researchers and investigators to translate discoveries into meaningful progress for patients."

Glioblastoma Research Highlights

• - University of Pennsylvania: In its updated findings, this institution presented outcomes focusing on overall survival rates and neurological function from a Phase 1 trial involving a bivalent CAR T-cell therapy for recurrent glioblastoma (Abstract 2013).
• - Dana-Farber Cancer Institute: They discussed a personalized neoantigen vaccine designed to target the unique immune landscape of glioblastoma (Abstract 2006).
• - Massachusetts General Hospital: Offered insights into the Phase 1 INCIPIENT trial examining rituximab pre-conditioning in CARv3-TEAM-E therapy for glioblastoma (Abstract 2059).

Melanoma Insights and Advances

• - TrioMBM (Stanford): A collaborative multicenter Phase 2 trial exploring the effectiveness of relatlimab, nivolumab, and ipilimumab in patients with both symptomatic and asymptomatic melanoma brain metastases (Abstract TPS9604).
• - OBX-115: New results from engineered tumor-infiltrating lymphocyte therapy in advanced melanoma patients who have progressed after immune checkpoint inhibitors (Abstract 9507).

Prostate Cancer Innovations

• - RiboX Study (PICI): Focused on a randomized Phase Ib/II trial assessing enzalutamide with or without ribociclib in patients with metastatic castration-resistant prostate cancer (Abstract 5057).
• - CHAMP Study: Offered a multicenter Phase 2 trial of chemoimmunotherapy for neuroendocrine or aggressive-variant metastatic prostate cancer (Abstract 5016).

Breast and Lung Cancer Developments

• - P-RAD (TBCRC-053): Provided crucial early results from a randomized trial integrating different preoperative radiation doses in triple-negative breast cancer patients (Abstract 1011).
• - RICHIS Study: Discussed a multicenter trial comparing radioimmunotherapy versus chemoimmunotherapy in treating non-small cell lung cancer (Abstract TPW8132).

Looking Ahead

The breadth of pivotal research presented by PICI at ASCO 2026 exemplifies the institute's proactive approach to tackling cancer through collaboration and innovation. With a track record of bridging the gap between scientific discovery and real-world application, PICI is set to continue leading the charge in transforming cancer immunotherapy, ultimately seeking to enhance patient outcomes worldwide.

For additional information and continuing updates regarding PICI’s initiatives and contributions at ASCO, please visit their website at Parker Institute.

• ---